Blood Pressure Targets in CKD: Lessons Learned from SPRINT and Previous Observational Studies

Area of Science:

• Nephrology
• Cardiology
• Clinical Trials

Background:

• Hypertension is a common comorbidity in chronic kidney disease (CKD) patients.
• Elevated blood pressure (BP) increases mortality, cardiovascular (CV) disease risk, and CKD progression.
• Optimal BP targets for CKD patients remain debated, especially with kidney damage.

Purpose of the Study:

• To review the Systolic Blood Pressure Intervention Trial (SPRINT) findings.
• To discuss the generalizability of a <120 mmHg systolic BP target to CKD patients.
• To evaluate the benefits of intensive BP lowering in CKD.

Main Methods:

• Review of the SPRINT trial, comparing intensive (<120 mmHg) versus standard (<140/90 mmHg) systolic BP targets.
• Analysis of observational studies on BP levels and mortality in CKD patients.
• Discussion of evidence regarding BP targets in CKD with kidney damage.

Main Results:

• The SPRINT trial indicated benefits of intensive BP lowering (<120 mmHg) on CV and all-cause mortality.
• Observational studies in CKD patients suggested increased mortality at systolic BP <120 mmHg.
• Contrasting evidence highlights the complexity of BP management in CKD.

Conclusions:

• The applicability of the SPRINT trial's intensive BP target (<120 mmHg) to the broader CKD population requires careful consideration.
• Further research is needed to establish definitive BP targets for CKD patients, balancing benefits and risks.
• Individualized treatment strategies may be necessary for hypertension management in CKD.